AMIT M. OZA MD, MBBS, FRCPC is Head of the Department of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret Cancer Centre (PMCC). Co-Director of The Bras Drug Development Program (BRAS DDP) at PMCC, Senior Scientist at The Ontario Cancer Institute, and Professor of Medicine at the University of Toronto.
Dr. Oza has been Pl and Co-Investigator in >100 phase l, ll and lll trials for gynecological cancer and advanced colorectal malignancies. He is current co-chair of the National Cancer Institute Gynecologic Cancer Steering Committee, and incoming Chair of the International Gynecologic Cancer InterGroup (GCIG).
Under Dr. Oza’s direction, the DDP gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials at PMCC. Under his direction, the group has participated or led seminal studies in gynecologic cancers that have led to the approval or use of targeted agents such as PARP inhibitors (olaparib, niraparib) and anti-angiogenic agents (bevacizumab) internationally
Over the last decade, Dr. Oza has been Pl/co-Pl of 19 grants totalling $43.3M from agencies such as the Canadian Cancer Society Research Institute, Canadian Institutes for Health Research, National Institutes of Health (NIH), Ontario Institute for Cancer Research, and the U.S. Department of Defense ($25.5m last 10 years).
Over Amit’s career, he has published >300 articles (all types) including Clinical Cancer Research (lF=10), JAMA Oncology (lF=20), New England Journal of Medicine (lF=79), Lancet Oncology (lF=36) and an invited seminar to CA: A Cancer Journal for Clinicians (lF=244). In Amit’s free time, he can be found trekking through Ontario’s vast hiking trails or photographing travel adventures across the globe.